FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
Why now
Thesis: FDA panel backs Galleri early-detection test
Catalyst to watch: Final FDA approval decision
Main risk: Approval still not guaranteed after panel vote
Why it matters
FDA panel backing a multi-cancer early detection test advances a diagnostic approval path, supporting early-detection adoption.
Details
SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee (the...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-23 22:17 UTC